Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (51-60 of 252) with videos related to

Pageof 26
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 18, 2009
Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphomaKatrin S Reiners, Axel Gossmann, Elke Pogge von Strandmann, et al.
Nuklearmedizin. Nuclear Medicine|October 14, 2025
Performance of a large language model in lymphoma stage assignment based on written PET/CT reportsConrad-Amadeus Voltin, Jonathan Kottlors, Peter Borchmann, et al.
European Journal of Haematology|February 5, 2024
Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantationNadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesFriederike Heuck, Julia Ellermann, Peter Borchmann, et al.
Onkologie|February 13, 2008
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's LymphomaRoland Schnell, Markus Dietlein, Klaus Schomäcker, et al.
British Journal of Haematology|October 30, 2009
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphomaBoris Böll, Peter Borchmann, Max S Topp, et al.
Hemasphere|November 15, 2019
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions UnansweredPeter Borchmann, Alexander Fosså, Monika Długosz-Danecka, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 14, 2025
Impact of pretreatment PET/MRI on radiooncologic target delineation in Hodgkin's lymphoma: a case seriesKai Kröger, Sebastian Lohmann, Michael Oertel, et al.
Journal of Clinical Psychology in Medical Settings|February 22, 2023
Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility StudyPeter Esser, Horst Müller, Peter Borchmann, et al.
Acta Oncologica (Stockholm, Sweden)|October 1, 2021
Volumetric modulated arc therapy versus intensity-modulated proton therapy in the irradiation of infra diaphragmatic Hodgkin Lymphoma in female patientsJohannes Rosenbrock, Christian Baues, Andres Vasquez-Torres, et al.
Pageof 26

Showing results (51-60 of 252) with videos related to

Sort By:
Pageof 26
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 18, 2009
Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphomaKatrin S Reiners, Axel Gossmann, Elke Pogge von Strandmann, et al.
Nuklearmedizin. Nuclear Medicine|October 14, 2025
Performance of a large language model in lymphoma stage assignment based on written PET/CT reportsConrad-Amadeus Voltin, Jonathan Kottlors, Peter Borchmann, et al.
European Journal of Haematology|February 5, 2024
Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantationNadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesFriederike Heuck, Julia Ellermann, Peter Borchmann, et al.
Onkologie|February 13, 2008
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's LymphomaRoland Schnell, Markus Dietlein, Klaus Schomäcker, et al.
British Journal of Haematology|October 30, 2009
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphomaBoris Böll, Peter Borchmann, Max S Topp, et al.
Hemasphere|November 15, 2019
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions UnansweredPeter Borchmann, Alexander Fosså, Monika Długosz-Danecka, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 14, 2025
Impact of pretreatment PET/MRI on radiooncologic target delineation in Hodgkin's lymphoma: a case seriesKai Kröger, Sebastian Lohmann, Michael Oertel, et al.
Journal of Clinical Psychology in Medical Settings|February 22, 2023
Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility StudyPeter Esser, Horst Müller, Peter Borchmann, et al.
Acta Oncologica (Stockholm, Sweden)|October 1, 2021
Volumetric modulated arc therapy versus intensity-modulated proton therapy in the irradiation of infra diaphragmatic Hodgkin Lymphoma in female patientsJohannes Rosenbrock, Christian Baues, Andres Vasquez-Torres, et al.
Pageof 26